Johnson & Johnson (JNJ)
167.57
-0.54 (-0.32%)
NYSE · Last Trade: Jul 30th, 11:50 AM EDT
Detailed Quote
Previous Close | 168.11 |
---|---|
Open | 167.70 |
Bid | 167.55 |
Ask | 167.59 |
Day's Range | 167.28 - 168.55 |
52 Week Range | 140.68 - 169.99 |
Volume | 1,299,226 |
Market Cap | 440.49B |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 5.200 (3.10%) |
1 Month Average Volume | 8,543,905 |
Chart
About Johnson & Johnson (JNJ)
Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More
News & Press Releases
Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, with more data expected.
Via Benzinga · July 29, 2025
The pharmaceutical industry could face a significant financial hit due to the new trade deal between the U.S. and the European Union (EU), potentially leading to increased drug prices and restricted access.
Via Benzinga · July 29, 2025
These top Dow dividend stocks have long dividend growth streaks.
Via The Motley Fool · July 28, 2025
If you're looking for high-yield stocks in the healthcare sector, it's hard to beat this trio of industry giants offering yields of up to 3.9%.
Via The Motley Fool · July 28, 2025
Plan now for a rotation away from riskier and volatile technology growth stocks and toward blue chips with more promise and predictability.
Via The Motley Fool · July 27, 2025
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.
Via Benzinga · July 26, 2025
US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may not happen soon.
Via Benzinga · July 25, 2025
Artificial intelligence (AI) has become one of the most exciting and volatile sectors in the stock market. As companies like (NASDAQ:NVDA), (NASDAQ:PLTR), and (NASDAQ:TSLA) drive innovation in everything from chips to autonomous software, retail and institutional investors alike are piling into AI stocks at record levels. But
Via MarketMinute · July 25, 2025
In a market where volatility creates both fear and opportunity, income-focused investors are increasingly turning to a lesser-known but powerful strategy: selling cash-secured puts. This options strategy not only allows investors to generate steady income, but it also provides a disciplined way to potentially acquire stocks at prices below current
Via MarketMinute · July 25, 2025
Johnson & Johnson (NYSE: JNJ) will present at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3rd, 2025. Management will participate in a Fireside Chat at 11:50 a.m. Eastern Time.
By Johnson & Johnson · Via Business Wire · July 24, 2025
With solid Q2 results and 2025 guidance increases, Wall Street is upgrading these four stocks. Analysts now see palpable upside in one streaming stalwart.
Via MarketBeat · July 23, 2025
Via The Motley Fool · July 23, 2025
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.
Via Benzinga · July 22, 2025
Apple expands retail presence in Saudi Arabia by launching online store and app, offering personalized support and localized experience.
Via Benzinga · July 22, 2025
Via FinancialNewsMedia · July 22, 2025
Three dividend-paying stocks with high yields present an opportunity for significant passive income but a potentially high dividend payout ratio.
Via MarketBeat · July 21, 2025
These S&P 500 dividend stocks have fallen by up to 33% and are best buys now.
Via The Motley Fool · July 20, 2025
Wall Street rose to new heights during the week amid strong earnings and solid economic data. Meanwhile, Fed rate cut debate heats up.
Via Benzinga · July 18, 2025
This week's M&A news includes strategic pivots and stumbles galore, with updates from WK Kellogg, Matador Restaurant and Windsurf.
Via Benzinga · July 18, 2025
Shares of Johnson & Johnson broke out of a classic ascending triangle pattern. They have since stalled out at resistance.
Via Benzinga · July 17, 2025
Three dividend stocks stand out in July, offering reliable income, attractive yields, and strong fundamentals to help investors navigate market volatility
Via MarketBeat · July 17, 2025
Johnson & Johnson earnings came in 3% higher than consensus. The company's operating leverage was "slightly diluted by higher tax."
Via Benzinga · July 17, 2025